Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
OBX · Why this verdict
Why Obsidian Therapeutics (OBX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Obsidian Therapeutics is a pre-revenue biotechnology stock down 73% from its high, with quality below the engine's floor and momentum failing, so the large analyst upside is not enough to justify a position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Business quality scores 3.0, below the 4.0 floor, with zero revenue and negative margins driving the exit-position signal. Bear case | Quality score rises back above 4.0 as losses narrow over the next 12 months. | →Stable |
| CounterA pre-revenue biotech is structurally scored low on margins; quality may say little about pipeline value. | ||
Momentum is weak at 2.5, below the engine's 4.5 threshold, with capitulation risk (RSI 27, below the 200-day average). Warnings | Momentum recovers above 4.5 and price reclaims its 200-day average. | →Stable |
| CounterAn RSI of 27 is oversold, so a mean-reversion bounce is plausible after a 73% drawdown. | ||
The price of $13.59 sits 143.9% below the analyst-derived take-profit of $33.15, giving an asymmetry ratio of 9.6. Targets | Price rallies toward the $33.15 target without breaching the $12.64 stop. | →Stable |
| CounterCoverage is light (3 analysts) so the target is dampened, and the stop is only 7% below price in a stock with a -73% drawdown. | ||
The latest reported quarter beat by 27% (-1.19 vs -1.63), but the earlier record shows 2 beats and 2 misses and revenue remains zero. Earnings | EPS losses keep narrowing and quarterly revenue starts to appear above $0. | →Stable |
| CounterBeats come against falling loss estimates, and zero revenue means there is no operating base to anchor valuation. | ||
At a $0.8B market cap the stock is below institutional reach, with a speculative classification and a recommendation to avoid. Edge rationale | Market cap grows beyond $1B, widening the institutional buyer base. | →Stable |
| CounterSmall-cap biotechs with no revenue often dilute shareholders to fund trials, which would cap any rerating. | ||
Business quality scores 3.0, below the 4.0 floor, with zero revenue and negative margins driving the exit-position signal.
→StableBear case
- Expectation
- Quality score rises back above 4.0 as losses narrow over the next 12 months.
CounterA pre-revenue biotech is structurally scored low on margins; quality may say little about pipeline value.
Momentum is weak at 2.5, below the engine's 4.5 threshold, with capitulation risk (RSI 27, below the 200-day average).
→StableWarnings
- Expectation
- Momentum recovers above 4.5 and price reclaims its 200-day average.
CounterAn RSI of 27 is oversold, so a mean-reversion bounce is plausible after a 73% drawdown.
The price of $13.59 sits 143.9% below the analyst-derived take-profit of $33.15, giving an asymmetry ratio of 9.6.
→StableTargets
- Expectation
- Price rallies toward the $33.15 target without breaching the $12.64 stop.
CounterCoverage is light (3 analysts) so the target is dampened, and the stop is only 7% below price in a stock with a -73% drawdown.
The latest reported quarter beat by 27% (-1.19 vs -1.63), but the earlier record shows 2 beats and 2 misses and revenue remains zero.
→StableEarnings
- Expectation
- EPS losses keep narrowing and quarterly revenue starts to appear above $0.
CounterBeats come against falling loss estimates, and zero revenue means there is no operating base to anchor valuation.
At a $0.8B market cap the stock is below institutional reach, with a speculative classification and a recommendation to avoid.
→StableEdge rationale
- Expectation
- Market cap grows beyond $1B, widening the institutional buyer base.
CounterSmall-cap biotechs with no revenue often dilute shareholders to fund trials, which would cap any rerating.
Per-dimension breakdown
Quality
3.0/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.9 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.9 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.5 |
| Volume | 5.3 |
- ▸Overbought bear rally (RSI 71)
- ▸Volume accumulation (rising OBV)
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 7.2 |
- ▸Analyst upside: 167%
- ▸Estimates rising as sentiment proxy (+5.6%)
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.8 |
| support resistance | 1.2 |
| 52w position | 0.0 |
| gap | 7.5 |
- ▸Extreme gap down (-6.1%) - potential reversal
Risk (lower is worse)
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| days to cover | 9.3 |
| volatility | 0.0 |
| beta | 1.2 |
| debt equity | 9.6 |
Catalyst
9.5/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 8.5 |
| earnings history | 10.0 |
| surprise avg | 10.0 |
- ▸Estimates up 5.6% (30d)
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (8)
- MOMENTUM:6.7>=5.5
- ASYMMETRY:8.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
8.48
Upside
+127.2%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Drawdown -71% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Catalyst at 9.5 and asymmetric R:R of 8.48.
The strongest dimensions are Catalyst at 9.5, Value at 9.0, and Insider at 7.3; the weakest are Technical at 2.4, Quality at 3.0, and Peer rank at 4.8. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 8.48 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Floor
Trip ifQuality score stays below 4.0 for 2 consecutive quarters.
- P2Momentum Gate Failing
Trip ifMomentum score falls below 2.0 from current 2.5.
- P3Large Analyst Upside
Trip ifShare price drops to $12.64 or below, hitting the stop loss.
- P4Earnings Record Mixed
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P5Small Cap Institutional Gap
Trip ifMarket cap falls below $0.5B from current $0.8B.